We are open to partnering, contact our team at
Melioidosis – the Disease
165,000
estimated cases per annum
54%
of cases are fatal
0
vaccines available
Late pre-clinical stage Melioidosis Vaccine Candidate
A new approach
Through an extensive characterisation of the protein structures present on the bacteria’s surface, the team at University College Dublin identified a homologue of the common OmpW bacterial antigen specific to this strain, called BpOmpW. Preclinical studies using this antigen showed significant survival benefit when challenged with the bacteria. Similarly, so-called correlates of protection, which provide an indication of the protection status of a subject, were much improved including increased IFN-γ production and an enhanced T-Cell response profile, both of which have a proven role in protection against Melioidosis.
Poolbeg in-licensed the product in September 2022.
![Istock 1252804949 1000px](https://wp-poolbeg-pharma-2021.s3.eu-west-2.amazonaws.com/media/2022/01/iStock-1252804949-1000px.jpg)
Efficacy data
![Burkholderia Pseudomallei](https://wp-poolbeg-pharma-2021.s3.eu-west-2.amazonaws.com/media/2022/09/Burkholderia-pseudomallei.png)
Burkholderia pseudomallei